Seres Therapeutics (MCRB) Expected to Announce Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($1.0050) per share and revenue of $6.35 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, topping the consensus estimate of ($2.18) by $2.65. The company had revenue of $0.74 million for the quarter, compared to the consensus estimate of $0.18 million. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%. On average, analysts expect Seres Therapeutics to post ($6.33) EPS for the current fiscal year and ($2.06) EPS for the next fiscal year.

Seres Therapeutics Price Performance

Shares of NASDAQ MCRB opened at $1.77 on Monday. The business has a fifty day simple moving average of $3.62 and a two-hundred day simple moving average of $7.19. The firm has a market cap of $17.78 million, a PE ratio of -0.73 and a beta of 0.31. Seres Therapeutics has a twelve month low of $1.68 and a twelve month high of $29.98.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MCRB shares. Weiss Ratings lowered Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.